Syntekabio joins forces with Enamine on AI-based synthetic drug development
The MoU will boost collaboration on compound supply, synthesis, and drug development at Syntekabio's ABS Center, integrating Enamine’s synthetic compound library into the latter’s DeepMatcher platform
